Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. - Wikidata - wikimedia - TriplyDB

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

http://www.wikidata.org/entity/Q37559606

about

Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?Recent advances in managing systemic sclerosis.Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice"Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis.Nintedanib for the treatment of idiopathic pulmonary fibrosis.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis.Nintedanib for Idiopathic Pulmonary Fibrosis.What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike!Usual interstitial pneumonia: typical, possible, and "inconsistent" patterns.Idiopathic pulmonary fibrosis: pathogenesis and management.Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis.Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Idiopathic Pulmonary Fibrosis (IPF): An Overview Diagnosis of Idiopathic Pulmonary Fibrosis in a Possible Usual Interstitial Pneumonia Pattern: a meta-analysis Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis

P2860

Q33814559-564A76D0-09F0-4AD0-AF80-4AE94004D847 Q33924950-1B1B1C5F-2D86-4DAE-AFCD-7AF3EF718A1E Q38598382-E462FF3E-6C40-4807-A296-A5D1C8D1DDCC Q38759138-42861B5B-F53F-4010-BCD8-3488A78B15D9 Q40272697-F3413339-6C87-4DBC-A23E-A0D23775314E Q41151927-3A866E9F-39E6-440C-9189-F7D8E68732B0 Q42101627-E1054B57-38AE-4416-AE80-CED451ACA26B Q43482585-01C1FAFB-7C8D-4074-8816-6148F69760F4 Q47365093-C091BAD7-3051-4660-99A3-CA0C9296B169 Q47658514-11A8AF3A-A438-40D5-B683-737F110C29D8 Q47791471-5AED4A77-0F05-42C5-8FDE-34DB38259F0A Q47792568-535500EB-311E-43D0-9D33-E3EEEA999843 Q47826077-6312BCF7-53BD-4186-9C6C-17CB4CADADEF Q48003254-1B4CD71E-1032-40F1-A517-1708A59414DD Q48551993-35AB5614-7C27-4DE6-AF4F-B18570679605 Q50326794-06B9A337-6D5B-43ED-BD63-9A6D230BE526 Q52659380-73E38BEE-97D3-4B47-B0AC-E7C484786A98 Q52797163-2227B709-D61A-425B-9872-2E8492945310 Q57170607-CBB11598-16D5-4A39-976E-68E20DFC684D Q58116140-FE0E484B-B8EE-4637-9D8C-5F48D70C903F Q58608704-87A7AE86-ED56-44E1-BDA7-461C0F200805 Q58698965-05F010BC-8D47-4BEC-9FAB-A761526BF430 Q58764186-16BA5D94-8240-45EA-84CB-A6B400D77B45

P2860

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

http://www.wikidata.org/entity/Q37559606

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@en

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@nl

type

label

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@en

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@nl

prefLabel

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@en

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@nl

P1433

Q37559606-98DC3423-31F3-4625-A3AA-BFABC0EC9834

P1476

Q37559606-F1AF70B6-2546-4467-962D-64B583BD5616

P2093

Q37559606-23E2911E-4C03-4828-B030-C78E34372EC1

Q37559606-2AF0DF64-1914-4FBD-81B2-9BC356D517B7

Q37559606-3991904B-1FFF-4D85-BCD4-709FDCAB6366

Q37559606-39EF58B8-EADC-4D8C-9467-00B69C1EDCDE

Q37559606-44857B05-7BB8-4B9F-B26E-5981F45AF77C

Q37559606-81975427-94F0-479E-BA48-31FF2238B4D1

Q37559606-87C71814-12F0-4A7A-9B89-DF721BFB5FB5

Q37559606-E1FD9225-D117-4A04-A748-365E7BDEC20B

P2860

Q37559606-013D0E36-647B-4B0A-894C-ED3AA9CA473E

Q37559606-0A50EE1E-D322-4C4E-A62D-6E9E8577596E

Q37559606-0A66B22D-E367-4E84-BE11-F8157C46F188

Q37559606-200B5ABD-75BD-44B6-80BB-363EEE9AE4A0

Q37559606-6A8DDA5E-7CDD-4389-93B9-3413BE4C864F

Q37559606-6BB54C7C-A922-4DE6-A332-917904F14181

Q37559606-6E085B0E-45AC-477E-A17E-80B09AFAB695

Q37559606-781A1B60-2D47-44B5-B5C2-BC7F8E3BACA2

Q37559606-8AF7AB49-E535-4632-B350-A8BCB0DC1314

Q37559606-971ABD6D-9837-42CC-B174-B0084046F227

P304

Q37559606-96D906B2-8C8E-4C44-919A-4E017CD2CB42

P31

Q37559606-D17E2AC4-012F-4091-BB43-491B620A3B9E

P356

Q37559606-A1461166-9016-43FE-99C8-951B04145D1D

P407

Q37559606-255B004A-84E2-4007-AC62-B1A77166CC08

P433

Q37559606-E40171F0-773B-4830-85DA-90A04FB91159

P478

Q37559606-4831EF5B-F361-4528-952B-9DB018B43772

P50

Q37559606-095EEF2B-B8ED-487A-B4EF-54A4E111869C

P577

Q37559606-77F5DCDE-3B55-4E02-9F1A-B96B40C5272E

P698

Q37559606-436E40D1-89BD-44F2-8800-AD3CAE23E851

P921

Q37559606-0766dc01-b190-4cfc-beb3-e75c35531240

Q37559606-D917F5B2-446E-471F-A807-3EB1A5E933AA

P932

Q37559606-29A05ABC-BD6F-4F58-8696-B186CE064EA1

P356

RCCM.201602-0402OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.

@en

P2093

Andrew G Nicholson

http://www.w3.org/2001/XMLSchema#string

Athol U Wells

http://www.w3.org/2001/XMLSchema#string

David M Hansell

http://www.w3.org/2001/XMLSchema#string

Florence Le Maulf

http://www.w3.org/2001/XMLSchema#string

Ganesh Raghu

http://www.w3.org/2001/XMLSchema#string

Kevin R Flaherty

http://www.w3.org/2001/XMLSchema#string

Rozsa Schlenker-Herceg

http://www.w3.org/2001/XMLSchema#string

Susanne Stowasser

http://www.w3.org/2001/XMLSchema#string

P2860

Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.

Interobserver variability in the CT assessment of honeycombing in the lungs.

Prevalence and prognosis of unclassifiable interstitial lung disease.

HRCT of fibrosing lung disease.

Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?

P304

78-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201602-0402OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

195

http://www.w3.org/2001/XMLSchema#string

P50

Pietro Battaglini

P577

2016-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27331880

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

5214917

http://www.w3.org/2001/XMLSchema#string